In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis?

Transfusion and Apheresis Science

Volumn 30, Issue 3, 2004, Pages 213-220

  Stegmayr, Bernd ^a   Lalau, Jean Daniel ^b   Johnson, Owe ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYSULFONE; SIMVASTATIN;

ANAPHYLAXIS; APHERESIS; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL PERSONNEL; MORBIDITY; MORTALITY; PATIENT SELECTION; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CORONARY DISEASE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME;

EID: 2542564960     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2003.12.002     Document Type: Conference Paper

References (33)

1. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-1503
2. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III). Jama 2001;285:2486-97
3. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
4. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 357:2001;577-581
5. Gale E., Anderson J. Diabetes mellitus and other disorders of metabolism. Kumar P., Clark M. Clinical medicine. 1999;989-998 W.B. Saunders, London
6. Marais A.D., Blom D.J., Firth J.C. Statins in homozygous familial hypercholesterolemia. Curr. Atheroscler. Rep. 4:2002;19-25
7. Yamamura T., Tajima S., Miyake Y., et al. Hyperlipoproteinemia as a risk factor for ischemic heart disease. Jpn. Circ. J. 54:1990;448-456
8. Cicero A.F.G., Braiato A., D'Addato S., Sangiorgi Z., Gaddi A. A suggestion for familial hypercholesterolemia (FH) heterozygosity clinical diagnosis based on epidemiological observations in a large Italian population. Int. J. Cardiol. 74:2000;5-11. discussion 13-4
9. Al-Shaikh A.M., Abdullah M.H., Barclay A., Cullen-Dean G., McCrindle B.W. Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia. Cardiol. Young. 12:2002;105-112
10. Yamamoto A., Harada-Shiba M., Kawaguchi A., Tsushima M. Apheresis technology for prevention and regression of atherosclerosis. Ther. Apher. 5:2001;221-225
11. Schettler V., Wieland E., Armstrong V.W., Kleinoeder T., Grunewald R.W., Muller G.A. First steps toward the establishment of a german low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management. Ther. Apher. 6:2002;381-383
12. Mabuchi H., Koizumi J., Shimizu M., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 82:1998;1489-1495
13. Kroon A.A., Aengevaeren W.R., van der Werf T., et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93:1996;1826-1835
14. Thompson G.R., Maher V.M., Matthews S., et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 345:1995;811-816
15. Schuff-Werner P., Gohlke H., Bartmann U., et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. The HELP-Study Group. Heparin-induced extra-corporeal LDL-precipitation. Eur. J. Clin. Invest. 24:1994;724-732
16. Norda R., Berseus O., Stegmayr B. Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfus. Apheresis. Sci. 25:2001;33-41
17. Mannheimer C., Camici P., Chester M.R., et al. The problem of chronic refractory angina; report from the ESC Joint Study Group on the treatment of refractory angina. Eur. Heart J. 23:2002;355-370
18. Schaumann D., Welch-Wichary M., Voss A., Schmidt H., Olbricht C.J. Prospective cross-over comparisons of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. Eur. J. Clin. Invest. 26:1996;1033-1038
19. Geiss H.C., Parhofer K.G., Donner M.G., Schwandt P. Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). Ther. Apher. 3:1999;199-202
20. Bambauer R., Schneidewind J.M., Latza R. Apheresis technologies for prevention and regression of atherosclerosis: clinical results. Asaio J. 45:1999;403-407
21. Bosch T., Lennertz A., Schmidt B., et al. DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood. Artif. Organs. 24:2000;81-90
22. Schmaldienst S., Banyai S., Stulnig T.M., et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis. 151:2000;493-499
23. Bosch T., Wendler T., Jaeger B.R., Samtleben W. Improvement of hemorheology by DALI apheresis: acute effects on plasma viscosity and erythrocyte aggregation in hypercholesterolemic patients. Ther. Apher. 5:2001;372-376
24. Empen K., Otto C., Brodl U.C., Parhofer K.G. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J. Clin. Apheresis. 17:2002;38-43
25. Wieland E., Schettler V., Armstrong V.W. Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. Atherosclerosis. 162:2002;187-191
26. Jaeger B.R., Meiser B., Nagel D., et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation. 96:1997;II-154-II-158
27. Schutz E., Schuff-Werner P., Guttner Y., Schulz S., Armstrong V.W. Investigations into the haemorheological significance of postprandial and fasting hypertriglyceridaemia. Eur. J. Clin. Invest. 23:1993;270-276
28. Schuff-Werner P., Schutz E., Seyde W.C., et al. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Eur. J. Clin. Invest. 19:1989;30-37
29. Pearson T.A., Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 160(4):2000;459-467
30. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. 2001, Eur Heart J 22(7):554-72
31. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl. J. Med. 344(26):2001;1959-1965
32. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Jama. 286(1):2001;64-70
33. Ekre O., Eliasson T., Norrsell H., Wahrborg P., Mannheimer C. Long-term effects of spinal cord stimulation and coronary artery bypass grafting on quality of life and survival in the ESBY study. Eur. Heart J. 23(24):2002;1938-1945